ADC Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $18,016 | $17,410 | $18,053 | $16,790 |
Gross Profit | 17,165 | 15,355 | 14,700 | 15,575 |
EBITDA | -35,564 | -22,516 | -32,664 | -26,963 |
EBIT | -36,366 | -23,354 | -33,507 | -27,974 |
Net Income | -43,969 | -36,544 | -46,606 | -85,031 |
Net Change In Cash | 18,016 | 17,410 | 18,053 | 16,790 |
Free Cash Flow | -25,259 | -31,604 | -44,626 | -33,400 |
Cash | 274,272 | 300,119 | 234,285 | 278,598 |
Basic Shares | 104,824 | 95,691 | 82,552 | 82,292 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $69,558 | $209,908 | $33,917 | $0 |
Gross Profit | 67,029 | 205,329 | 32,524 | -1,972 |
EBITDA | -146,762 | -108,055 | -223,715 | -219,263 |
EBIT | -150,029 | -110,443 | -226,345 | -221,235 |
Net Income | -240,053 | -155,800 | -230,026 | -246,290 |
Net Change In Cash | 69,558 | 209,908 | 33,917 | 0 |
Free Cash Flow | -121,902 | -139,092 | -239,754 | -171,538 |
Cash | 278,598 | 326,441 | 466,544 | 439,195 |
Basic Shares | 81,712 | 78,152 | 76,748 | 65,410 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.42 |
2024-06-30 | -$0.38 |
2024-03-31 | -$0.56 |
2023-12-31 | -$1.03 |
